

CORRECTION

Correction: Clinical review: Prothrombin complex concentrates - evaluation of safety and thrombogenicity

Benny Sørensen^{1*}, Donat R Spahn², Petra Innerhofer³, Michael Spannagl⁴ and Rolf Rossaint⁵

See related review by Sørensen *et al.*, <http://ccforum.com/content/15/1/201>

Correction

After publication of our article [1] we noted that in Table 1 for Prothrombinex-VF 'Antithrombin and heparin added' should have been included under the 'Additional information' column. A copy of the table with the correct information can be found overleaf.

Author details

¹Haemostasis Research Unit, Centre for Haemostasis and Thrombosis, Department of Haematology and Oncology, Guy's and St Thomas' Hospital & NHS Trust Foundation, King's College London School of Medicine, 1st Floor, North Wing, St Thomas' Hospital, Westminster Bridge Road, London SE1 7EH, UK. ²Institute of Anesthesiology, University Hospital Zurich, CH-8091 Zurich, Switzerland. ³Department of Anaesthesiology and Critical Care Medicine, Innsbruck Medical University, Anichstrasse 35, A-6020 Innsbruck, Austria. ⁴Working Group on Perioperative Hemostasis, Department of Anaesthesiology, University Hospital of Munich, Nussbaumstrasse 20, 80336 Munich, Germany. ⁵Department of Anaesthesiology, University Hospital Aachen, RWTH Aachen University, Pauwelsstrasse 30, 52074 Aachen, Germany.

Published: 18 March 2011

Reference

1. Sørensen B, Spahn DR, Innerhofer P, Spannagl M, Rossaint R: **Clinical review: Prothrombin complex concentrates - evaluation of safety and thrombogenicity.** *Crit Care* 2011, **15**:201.

doi:10.1186/cc10094

Cite this article as: Sørensen B, *et al.*: Correction: Clinical review: Prothrombin complex concentrates - evaluation of safety and thrombogenicity. *Critical Care* 2011, **15**:409.

*Correspondence: benny.sorensen@kcl.ac.uk

¹Haemostasis Research Unit, Centre for Haemostasis and Thrombosis, Department of Haematology and Oncology, Guy's and St Thomas' Hospital & NHS Trust Foundation, King's College London School of Medicine, 1st Floor, North Wing, St Thomas' Hospital, Westminster Bridge Road, London SE1 7EH, UK
Full list of author information is available at the end of the article

Table 1. Composition of PCCs in the World Federation of Hemophilia register of clotting factor concentrates

| Brand name | Manufacturer | International units relative to factor IX | | | | Viral inactivation | Additional information |
|-------------------|--------------------------------|---|------------|-----------|----------|--|--|
| | | Factor II | Factor VII | Factor IX | Factor X | | |
| Bebulin VH | Baxter BioScience, Austria | 120 | (13) | 100 | 100 | Vapour heat, 60°C for 10 hours at 190 mbar, then 80°C for 1 hour at 375 mbar | Heparin added |
| Beriplex P/N | CSL Behring, Germany | 128 | 68 | 100 | 152 | Pasteurisation at 60°C for 10 hours, and nanofiltration | Protein C; antithrombin, heparin and albumin added |
| Cofact | Sanquin, the Netherlands | 56-140 | 28-80 | 100 | 56-140 | Solvent/detergent and 15 nm nanofiltration | Antithrombin added |
| KASKADIL | LFB, France | 148 | 40 | 100 | 160 | Solvent/detergent | Heparin added |
| Octaplex | Octapharma, Austria and France | 44-152 | 36-96 | 100 | 50 | Solvent/detergent and nanofiltration | Heparin added; low activated factor VII content |
| Profilnine SD | Grifols, USA | 148 | (11) | 100 | 64 | Solvent/detergent | – |
| Prothrombinex VF | CSL Bioplasma, Australia | 100 | (–) | 100 | 100 | Dry heat, 80°C for 72 hours and nanofiltration | Antithrombin and heparin added |
| Prothromplex T | Baxter BioScience, Austria | 100 | 85 | 100 | 100 | Vapour heat, 60°C for 10 hours at 190 mbar, then 80°C for 1 hour at 375 mbar | Antithrombin and heparin added |
| UMAN Complex D.I. | Kedrion, Italy | 100 | (–) | 100 | 80 | Solvent/detergent and dry heat, 100°C for 30 minutes | Antithrombin and heparin added |

Composition of prothrombin complex concentrates (PCCs) listed in the World Federation of Hemophilia register of clotting factor concentrates [54], excluding concentrates for national markets only or for which the concentrations of factors relative to factor IX were not available from the relevant product information sheets. Factor VII presented in parentheses for three-factor PCCs.